2016-11-08
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
Publication
Publication
British Journal of Cancer , Volume 115 - Issue 10 p. 1174- 1178
Background:It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis.Methods:We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC.Results:BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HR mult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HR mult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HR mult 1.15; 95% CI 0.84-1.57) and OCSS (HR mult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HR mult 1.99; 95% CI 1.21-3.31).Conclusions:Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.
| Additional Metadata | |
|---|---|
| , , , , | |
| doi.org/10.1038/bjc.2016.333, hdl.handle.net/1765/96986 | |
| British Journal of Cancer | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Zaaijer, L.H. (Leendert H.), Van Doorn, H.C. (Helena C.), Mourits, M., van Beurden, M., de Hullu, J., Adank, M., … Kriege, M. (Mieke). (2016). Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 115(10), 1174–1178. doi:10.1038/bjc.2016.333 |
|
